

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1-15. (canceled).

16 (new): A compound of 2-[(2-[(1R,2R)-2-[(1E)-4-hydroxy-4-methyl-1-nonenyl]-5-oxocyclopentyl]ethyl)sulfanyl]-1,3-thiazole-4-carboxylic acid,

an R-configuration or an S-configuration thereof due to the presence of an asymmetric carbon, a salt thereof, an N-oxide thereof, an S-oxide thereof, a solvate thereof or a prodrug thereof, or a cyclodextrin clathrate thereof.

17. (new): The compound according to claim 16, which is 2-[(2-[(1R,2R)-2-[(1E)-4-hydroxy-4-methyl-1-nonenyl]-5-oxocyclopentyl]ethyl)sulfanyl]-1,3-thiazole-4-carboxylic acid or a salt thereof.

18. (new): The compound according to claim 16, which is the R-configuration of 2-[(2-[(1R,2R)-2-[(1E)-4-hydroxy-4-methyl-1-nonenyl]-5-oxocyclopentyl]ethyl)sulfanyl]-1,3-thiazole-4-carboxylic acid or a salt thereof.

19. (new): The compound according to claim 16, which is the S-configuration of 2-[(2-[(1R,2R)-2-[(1E)-4-hydroxy-4-methyl-1-nonenyl]-5-oxocyclopentyl]ethyl)sulfanyl]-1,3-thiazole-4-carboxylic acid or a salt thereof.